All Stories

  1. Depression and Cognitive Function in Mild Cognitive Impairment: A 1-Year Follow-Up Study
  2. Quetiapine augmentation for depression
  3. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles
  4. The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder
  5. Delays in depression treatment among Korean population
  6. Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
  7. Influence of the number and severity of somatic symptoms on the severity of depression and suicidality in community-dwelling elders
  8. A review of current evidence for acetyl-l-carnitine in the treatment of depression
  9. Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students
  10. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression
  11. Aripiprazole augmentation for major depressive disorder
  12. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study
  13. Epistatic Interactions between CREB and CREM Variants in Affective Disorder
  14. Metabolic Syndrome and Early Carotid Atherosclerosis in the Elderly
  15. A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises
  16. Variables Influencing Subjective Well-Being in Patients with Schizophrenia
  17. Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
  18. Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole
  19. Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder
  20. Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram
  21. Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants
  22. Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder
  23. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
  24. Dilemma for enhancing psychiatrists’ adherence to guideline (evidence)-based practice
  25. Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: a meta-analysis
  26. Investigation of Epistasis Between DAOA and 5HTR1A Variants on Clinical Outcomes in Patients with Schizophrenia
  27. A review of current evidence for vilazodone in major depressive disorder
  28. Experiences and barriers to implementation of clinical practice guideline for depression in Korea
  29. Do We Need to Consider Ethno-cultural Variation in the Use of Atypical Antipsychotics for Asian Patients with Major Depressive Disorder?
  30. Management of Chronic Depressive Patients with Residual Symptoms
  31. Evidence for the Benefits of Nonantipsychotic Pharmacological Augmentation in the Treatment of Depression
  32. Atypical antipsychotics as a possible treatment option for irritable bowel syndrome
  33. Alexithymia and low cooperativeness are associated with suicide attempts in male military personnel with adjustment disorder: A case–control study
  34. Diagnosis and treatment of dementia in primary care
  35. Oral scopolamine augmentation for major depression
  36. Distinguishing Quantitative Electroencephalogram Findings between Adjustment Disorder and Major Depressive Disorder
  37. A Normative Study of Lexical Verbal Fluency in an Educationally-Diverse Elderly Population
  38. Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder
  39. Increased Carotid Intima-Media Thickness and Plasma Homocysteine Levels Predict Cardiovascular and All-Cause Death: A Population-Based Cohort Study
  40. Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I) : Initial Choice of Antidepressant Treatment
  41. Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (II) : Antidepressant Efficacy Compared with Placebo, Difference in Efficacy of Antidepressants, and Appropriate Time of Efficacy Judgment in Antidepressant Therapy
  42. Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (III) : Dose Increment, Switching, Combination, and Augmentation Strategy in Antidepressant Therapy
  43. Distressed personality without a partner enhances the risk of depression in patients with coronary heart disease
  44. Temperament and Character of Young Male Conscripts With Adjustment Disorder
  45. Can botulinum toxin improve mood in depressed patients?
  46. Bright light therapy as an adjunctive treatment with risperidone in patients with delirium: a randomized, open, parallel group study
  47. Characteristics of Type D personality in Korean adolescents
  48. Paliperidone
  49. Paliperidone
  50. Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients
  51. Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder
  52. Combination Treatment With Aripiprazole and Valproic Acid for Acute Mania
  53. Attitudes on clinical research participation of community living elders in Korea
  54. Association Between Visceral Obesity and Sarcopenia and Vitamin D Deficiency in Older Koreans: The Ansan Geriatric Study
  55. Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia
  56. Association of chronic divalproex sodium use and brain atrophy in Alzheimer’s disease
  57. Symptom severity and attitudes toward medication: Impacts on adherence in outpatients with schizophrenia
  58. Standardization of the Korean Version of the Posttraumatic Embitterment Disorder Self-Rating Scale
  59. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia
  60. Interactive influences of demographics on the Mini-Mental State Examination (MMSE) and the demographics-adjusted norms for MMSE in elderly Koreans
  61. Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients
  62. Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics
  63. Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia
  64. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder
  65. Do we need more than one antidepressant for patients with major depressive disorder?
  66. Region and frequency specific changes of spectral power in Alzheimer’s disease and mild cognitive impairment
  67. Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment
  68. Case–control association study ofGRIA1,GRIA2andGRIA4polymorphisms in bipolar disorder
  69. Uptake of Web-Based Clinical Resources from the MacArthur Initiative on Depression and Primary Care
  70. Depression Is Associated with Sarcopenia, Not Central Obesity, in Elderly Korean Men
  71. DRD2/ANKK1 TaqI A polymorphism affects corticostriatal activity in response to negative affective facial stimuli
  72. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial
  73. Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia
  74. DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes
  75. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease
  76. Association of sedative–hypnotic medications with suicidality
  77. Paliperidone-associated atypical neuroleptic malignant syndrome: A case report
  78. Embitterment in Asia: Losing face, inequality, and alienation under historical and modern perspectives
  79. Depression, suicide, and Korean society
  80. Safety and Tolerability of Lamotrigine
  81. Assessment of the Type D Personality Construct in the Korean Population: A Validation Study of the Korean DS14
  82. Serum Homocysteine and Folate Levels are Associated With Late-life Dementia in a Korean Population
  83. Lack of association between antisperm antibodies and language dysfunction in Alzheimer's disease
  84. Low Levels of Plasma Agmatine in the Metabolic Syndrome
  85. Paroxetine mesylate: comparable to paroxetine hydrochloride?
  86. The cutoff values of visceral fat area and waist circumference for identifying subjects at risk for metabolic syndrome in elderly Korean: Ansan Geriatric (AGE) cohort study
  87. Milnacipran
  88. Psychometric Properties of the Patient Health Questionnaire–15 (PHQ–15) for Measuring the Somatic Symptoms of Psychiatric Outpatients
  89. Adiposity parameters and cognitive function in the elderly: Application of “Jolly Fat” hypothesis to cognition
  90. Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients
  91. Thyroid hormones affect recovery from depression during antidepressant treatment
  92. Methylphenidate Extended Release (OROS MPH) for the Treatment of Antidepressant-Related Sexual Dysfunction in Patients With Treatment-Resistant Depression
  93. The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry
  94. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects
  95. Study design and methods of the Ansan Geriatric Study (AGE study)
  96. Duloxetine: An emerging evidence for fibromyalgia
  97. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study
  98. History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release
  99. Manganese superoxide dismutase gene Ala–9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients
  100. Mental health economics, health service provision, and the practice of geriatric psychiatry
  101. Paroxetine: safety and tolerability issues
  102. An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly Koreans: Demographic influence and population-based norms (the AGE study)
  103. History of Depressive and Anxiety Disorders and Paroxetine Response in Patients With Irritable Bowel Syndrome
  104. Attitudes of patients and family members towards implantable psychiatric medication
  105. Delirium: Underrecognized and undertreated
  106. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients
  107. The relationship between fibromyalgia and major depressive disorder: a comprehensive review
  108. P4‐139: Body fat composition and cognitive dysfunction in the elderly Korean
  109. An Open-Label, Rater-Blinded, Flexible-Dose, 8-Week Trial of Escitalopram in Patients With Major Depressive Disorder With Atypical Features
  110. Does minocycline have antidepressant effect?
  111. Delirium: Where do we stand?
  112. Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study
  113. A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?
  114. Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study
  115. Reply to Dr Ng's Comments on "A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation With An Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression"
  116. Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder
  117. Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial
  118. Comments on “Addition of lamotrigine to valproic acid: A successful outcome in a case of rapid-cycling bipolar affective disorder”
  119. Awareness of putative risk factors for Alzheimer’s disease among elderly Koreans
  120. Does Neurotropin-3 Have a Therapeutic Implication in Major Depression?
  121. Val158Met Polymorphism in the Catechol-<i>O</i>-Methyltransferase (<i>COMT)</i> Gene Is Not Associated with Tardive Dyskinesia in Schizophrenia
  122. Venlafaxine versus Mirtazapine in the??Treatment of Undifferentiated Somatoform Disorder
  123. Association Study between Antipsychotics- Induced Restless Legs Syndrome and Polymorphisms of Dopamine D1, D2, D3, and D4 Receptor Genes in Schizophrenia
  124. Prevalence of Dementia and Its Subtypes in an Elderly Urban Korean Population: Results from the Korean Longitudinal Study on Health and Aging (KLoSHA)
  125. Possible association between the −2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain
  126. Attitudes Towards Implantable Psychiatric Medication Survey
  127. Carotid intima‐media thickness in Parkinson's disease
  128. Possible association between G-protein β3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia
  129. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion
  130. Effects of Methylphenidate and Bupropion on DHEA-S and Cortisol Plasma Levels in Attention-deficit Hyperactivity Disorder
  131. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder
  132. Selegiline transdermal system: Current awareness and promise
  133. A Glu487Lys polymorphism in the gene for mitochondrial aldehyde dehydrogenase 2 is associated with myocardial infarction in elderly Korean men
  134. Characteristics and clinical correlates of restless legs syndrome in schizophrenia
  135. Reply to Comments on “Low Plasma BDNF is associated with Suicidal Behavior in Major Depression”, Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006
  136. Low plasma BDNF is associated with suicidal behavior in major depression
  137. Usefulness of Beck Depression Inventory (BDI) in the Korean elderly population
  138. Increased plasma nitric oxide level associated with suicide attempt in depressive patients
  139. Mental Health of Healthcare Workers who Experience Needlestick and Sharps Injuries
  140. Increased Plasma Nitric Oxide Metabolites in Suicide Attempters
  141. Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics
  142. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients